Indian scientists discovered genomic factors responsible for breast cancer therapy resistance.
Tata Memorial Centre (TMC), Mumbai, and the National Institute of Biomedical Genomics (NIBMG), Kalyani discovered genomic factors responsible for resistance to hormone (endocrine) therapy in oestrogen receptor-positive (ER+) breast cancer.
These findings will provide crucial insights into why some patients do not respond or stop responding to hormone therapy.
It will help in developing new targeted treatment strategies.
These findings offer significant clinical implications, including the potential repurposing of DNA-damaging drugs for patients who develop hormone therapy resistance.
Breast cancer is the most frequently diagnosed cancer among women in India. 28.2% of all female cancer cases are breast cancer.
Around 50-60% are oestrogen receptor-positive, meaning the cancer cells releases a protein called oestrogen receptor (ER), which makes them susceptible to hormone therapy.
